Cinqaero (reslizumab)
- Region
- 🇪🇺 EU
- Active substance
- reslizumab
- Company
- Teva B.V.
- Status
- Authorised
- Therapeutic area
- Asthma
- CHMP opinion
- Wed 22 Jun 2016
- EU approval
- Mon 15 Aug 2016
- Application
- EMEA/H/C/003912
- ATC
- R03DX08
- Official record
- www.ema.europa.eu
Indication
Cinqaero is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.
Regulatory milestones
No milestones recorded in the last year.
Follow Cinqaero
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.